AUA 2022
In-depth coverage of AUA 2022
Plenary highlights from AUA 2022, including non-muscle invasive bladder cancer treatments and the SPOTLIGHT study.
Focal ablative salvage therapy may confer good oncological control for patients with recurrent cancer.
The mental health data comes from one of the largest randomized-controlled trials to date.
Estimation of life expectancy is critical for evaluating the benefit of PSA screening for prostate cancer.
Researchers evaluated a hypothetical pragmatic trial of adjuvant radiotherapy in patients with pN1 prostate cancer.
Minorities experience disparities in shared decision-making when it comes to discussions on the advantages of PSA testing.
The findings suggest potential opportunities for more targeted therapy in aggressive prostate cancer.
Research findings show the benefits of vegetarian, vegan, and other plant-based diets for patients with prostate cancer.
Uptake of active surveillance remains suboptimal for patients with low-risk prostate cancer.
The therapy represents a valuable strategy in select patients whose disease fails to respond to initial cryoablation or HIFU.
The tricyclic antidepressant may suppress the progression of prostate cancer following radical prostatectomy,
The results highlight the need for urologists to consider baseline urinary symptoms in treatment decision-making.
This use of molecular MRI with targeted agents can enhance tumor margin detection and inform treatment decision-making.
Advertisement
Advertisement
